Transverse Medical

Executive Summary

Transverse Medical is a private medical device company founded in 2018 and headquartered in San Carlos, California, focused on stroke prevention during coronary procedures. The company's lead product, POINT-GUARD™, is designed to provide comprehensive embolic protection during transcatheter aortic valve replacement (TAVR) and other high-risk coronary interventions, aiming to reduce the incidence of periprocedural stroke. While the company has not disclosed funding or valuation data, its presence in the cardiovascular device space and focus on a critical unmet need—stroke prevention in structural heart procedures—positions it as a potential innovator in a growing market. As the TAVR market expands with expanded indications, the demand for effective cerebral protection devices is likely to increase. Transverse Medical's success will hinge on regulatory clearance, clinical evidence demonstrating superiority or equivalence to existing protection devices, and commercial adoption by interventional cardiologists. The company's current profile suggests an early commercial stage with limited public information, making it a speculative but potentially high-impact opportunity.

Upcoming Catalysts (preview)

• Q2 2027FDA Pre-Market Approval or 510(k) Clearance for POINT-GUARD™60% success
• Q4 2026Publication of Pivotal Clinical Trial Results50% success
• Q2 2026Strategic Partnership or Distribution Agreement with a Major Cardiovascular Company40% success